跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Cost-Effectiveness of Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain in Taiwan
Emma Gray
, Xin Ye
*
, Yen Feng Wang
,
Shuu Jiun Wang
*
此作品的通信作者
醫學系
腦科學研究中心
研究成果
:
Article
›
同行評審
5
引文 斯高帕斯（Scopus）
總覽
指紋
指紋
深入研究「Cost-Effectiveness of Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain in Taiwan」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Taiwan
100%
Cost-effectiveness
100%
Mirogabalin
100%
Diabetic Neuropathic Pain
100%
Quality-adjusted Life Years
83%
Health Status
66%
Pain Score
66%
Daily Pain
50%
Incremental Cost-effectiveness Ratio
50%
Treatment Options
33%
Placebo
33%
Cost-effective Treatment
33%
Pregabalin
33%
Medical Experts
16%
Utility Value
16%
Taiwanese
16%
Taiwan National Health Insurance
16%
Resource Use
16%
Probabilistic Analysis
16%
Resource Cost
16%
Third-party Perspective
16%
Markov Model
16%
Cost Data
16%
Economic Analysis
16%
Efficacy Data
16%
Severe Pain
16%
Change Score
16%
Phase III Clinical Trial
16%
Deterministic Analysis
16%
Willingness-to-pay Threshold
16%
Network Meta-analysis
16%
One-way Sensitivity Analysis
16%
Incremental Cost
16%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Health Care Cost
100%
Neuropathic Pain
100%
Mirogabalin
100%
Quality Adjusted Life Year
100%
Health Status
80%
Placebo
40%
Pregabalin
40%
Base
20%
Clinical Trial
20%
Network Meta-Analysis
20%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Neuropathic Pain
100%
Quality Adjusted Life Year
100%
Mirogabalin
100%
Health Status
80%
Incremental Cost-Effectiveness Ratio
60%
Placebo
40%
Pregabalin
40%
National Health Insurance
20%
Base
20%
Network Meta-Analysis
20%
Economic Analysis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Mirogabalin
100%
Neuropathic Pain
100%
Health Status
80%
Placebo
40%
Pregabalin
40%
Clinical Trial
20%
Base
20%